AIMS: Well-differentiated lipomatous neoplasms encompass a broad spectrum of benign and malignant tumours, many of which are characterised by recurrent genetic abnormalities. Although a key regulator of p53 signalling, MDM2, is characteristically amplified in well-differentiated liposarcoma, recurrent abnormalities of p53 itself have not been reported in well-differentiated adipocytic neoplasms. Here, we present a series of well-differentiated lipomatous tumours characterised by p53 alterations and histological features in keeping with atypical pleomorphic lipomatous tumour (APLT). METHODS AND RESULTS: We reviewed the morphological, immunohistochemical and molecular genetic features of eight lipomatous tumours with p53 alterations. Four tumours arose in the thigh, and one case each arose in the shoulder, calf, upper back, and subclavicular regions; six tumours were deep/subfascial and two were subcutaneous. Relevant clinical history included two patients with Li-Fraumeni syndrome. Morphologically, all cases showed well-differentiated adipocytes with prominent nuclear pleomorphism, limited mitotic activity, and no tumour cell necrosis. All cases were negative for MDM2 overexpression and amplification as determined with immunohistochemistry and fluorescence in-situ hybridisation, respectively. Immunohistochemically, p16 was diffusely overexpressed in all cases; seven tumours (88%) showed abnormal loss of Rb and p53. TP53 mutation or deletion was identified in four of six tumours evaluated with exon-targeted hybrid capture-based massively parallel sequencing; RB1 mutation or deletion was present in five of six cases. CONCLUSIONS: We present a series of eight well-differentiated lipomatous neoplasms characterised by p53 alterations in addition to Rb loss and histological features of APLT. These findings suggest that impaired p53 signalling may contribute to the pathogenesis of APLT in a subset of cases.
AIMS: Well-differentiated lipomatous neoplasms encompass a broad spectrum of benign and malignant tumours, many of which are characterised by recurrent genetic abnormalities. Although a key regulator of p53 signalling, MDM2, is characteristically amplified in well-differentiated liposarcoma, recurrent abnormalities of p53 itself have not been reported in well-differentiated adipocytic neoplasms. Here, we present a series of well-differentiated lipomatous tumours characterised by p53 alterations and histological features in keeping with atypical pleomorphic lipomatous tumour (APLT). METHODS AND RESULTS: We reviewed the morphological, immunohistochemical and molecular genetic features of eight lipomatous tumours with p53 alterations. Four tumours arose in the thigh, and one case each arose in the shoulder, calf, upper back, and subclavicular regions; six tumours were deep/subfascial and two were subcutaneous. Relevant clinical history included two patients with Li-Fraumeni syndrome. Morphologically, all cases showed well-differentiated adipocytes with prominent nuclear pleomorphism, limited mitotic activity, and no tumour cell necrosis. All cases were negative for MDM2 overexpression and amplification as determined with immunohistochemistry and fluorescence in-situ hybridisation, respectively. Immunohistochemically, p16 was diffusely overexpressed in all cases; seven tumours (88%) showed abnormal loss of Rb and p53. TP53 mutation or deletion was identified in four of six tumours evaluated with exon-targeted hybrid capture-based massively parallel sequencing; RB1 mutation or deletion was present in five of six cases. CONCLUSIONS: We present a series of eight well-differentiated lipomatous neoplasms characterised by p53 alterations in addition to Rb loss and histological features of APLT. These findings suggest that impaired p53 signalling may contribute to the pathogenesis of APLT in a subset of cases.
Authors: David Creytens; Joost van Gorp; Suvi Savola; Liesbeth Ferdinande; Thomas Mentzel; Louis Libbrecht Journal: Virchows Arch Date: 2014-07 Impact factor: 4.064
Authors: Michael A den Bakker; Dorine T den Toom; Tim H C Damen; Hein F B M Sleddens; Isabella C Meijssen; Stijn Deloose; Mike Kliffen; Winand N M Dinjens Journal: Int J Surg Pathol Date: 2020-05-04 Impact factor: 1.271
Authors: Michael Michal; Dmitry V Kazakov; Ladislav Hadravsky; Kvetoslava Michalova; Petr Grossmann; Petr Steiner; Tomas Vanecek; Valentina Renda; Saul Suster; Michal Michal Journal: Hum Pathol Date: 2017-05-23 Impact factor: 3.466
Authors: C D Fletcher; M Akerman; P Dal Cin; I de Wever; N Mandahl; F Mertens; F Mitelman; J Rosai; A Rydholm; R Sciot; G Tallini; H van den Berghe; W van de Ven; R Vanni; H Willen Journal: Am J Pathol Date: 1996-02 Impact factor: 4.307
Authors: Rita Alaggio; Cheryl M Coffin; Sharon W Weiss; Julia A Bridge; Josephine Issakov; Andre M Oliveira; Andrew L Folpe Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394
Authors: Jo Van Dorpe; Uta Flucke; David Creytens; Andrew L Folpe; Christian Koelsche; Thomas Mentzel; Liesbeth Ferdinande; Joost M van Gorp; Malaïka Van der Linden; Lennart Raman; Björn Menten; Karen Fritchie; Andreas von Deimling Journal: Mod Pathol Date: 2021-06-24 Impact factor: 7.842